ATE213944T1 - Verwendung von immunomodulatoren - Google Patents

Verwendung von immunomodulatoren

Info

Publication number
ATE213944T1
ATE213944T1 AT98917808T AT98917808T ATE213944T1 AT E213944 T1 ATE213944 T1 AT E213944T1 AT 98917808 T AT98917808 T AT 98917808T AT 98917808 T AT98917808 T AT 98917808T AT E213944 T1 ATE213944 T1 AT E213944T1
Authority
AT
Austria
Prior art keywords
immunomodulators
pka
well
pharmaceutical compositions
protein kinase
Prior art date
Application number
AT98917808T
Other languages
English (en)
Inventor
Kjetil Tasken
Einar Martin Aandahl
Pael Aukrust
Bjoern S Skalhegg
Fredrik Mueller
Stig Froeland
Vidar Hansson
Original Assignee
Lauras As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lauras As filed Critical Lauras As
Application granted granted Critical
Publication of ATE213944T1 publication Critical patent/ATE213944T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
AT98917808T 1997-04-29 1998-04-29 Verwendung von immunomodulatoren ATE213944T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler
PCT/NO1998/000134 WO1998048809A1 (en) 1997-04-29 1998-04-29 Use of immunomodulating agents

Publications (1)

Publication Number Publication Date
ATE213944T1 true ATE213944T1 (de) 2002-03-15

Family

ID=19900676

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98917808T ATE213944T1 (de) 1997-04-29 1998-04-29 Verwendung von immunomodulatoren

Country Status (13)

Country Link
US (1) US20050250727A1 (de)
EP (1) EP1024809B1 (de)
JP (2) JP2002501499A (de)
AT (1) ATE213944T1 (de)
AU (1) AU738674B2 (de)
CA (1) CA2288215C (de)
DE (1) DE69804125T2 (de)
DK (1) DK1024809T3 (de)
ES (1) ES2171018T3 (de)
NO (1) NO971997D0 (de)
NZ (1) NZ501181A (de)
PT (1) PT1024809E (de)
WO (1) WO1998048809A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080186A2 (de) * 1998-05-27 2001-03-07 Lauras AS Verfahren zur modifizierung der aktivität von proteinen der pka signaltransduktionskaskade
MXPA01007366A (es) * 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
WO2001042470A1 (en) * 1999-12-07 2001-06-14 University Of Medicine And Dentistry Of New Jersey Nucleic acid and protein expressed thereby and their involvement in stress
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
WO2005060996A2 (en) * 2003-12-23 2005-07-07 Lauras As Method of altering the pka type i signalling pathway
GB0413726D0 (en) 2004-06-18 2004-07-21 Lauras As Compounds
GB0421355D0 (en) * 2004-09-24 2004-10-27 Univ Oslo Inhibitors
GB0518027D0 (en) * 2005-09-05 2005-10-12 Birkeland Innovasjon As Compounds
GB0618235D0 (en) 2006-09-15 2006-10-25 Lauras As Process
JP6529486B2 (ja) 2013-06-05 2019-06-12 バイオタイム インク．Ｂｉｏｔｉｍｅ Ｉｎｃ． 哺乳動物種における誘導組織再生のための組成物および方法
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CA3007733A1 (en) 2015-12-07 2017-06-15 Biotime, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
US20230285556A1 (en) * 2021-09-13 2023-09-14 Omeros Corporation Methods and compositions for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
US5276017A (en) * 1990-09-14 1994-01-04 Trustees Of The University Of Pennsylvania Therapeutic and diagnostic applications of tropho-uteronectin (TUN) manipulation
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
WO1993021929A1 (en) * 1992-05-01 1993-11-11 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phosphorothioate derivatives of cyclic amp analogues
ATE312188T1 (de) * 1993-01-22 2005-12-15 Univ Research Corp Lokalisierung von therapeutischen mitteln
US5807693A (en) * 1994-11-23 1998-09-15 Icos Corporation Calcineurin inhibitory compounds and anchoring protein
US5795735A (en) * 1995-07-17 1998-08-18 Icos Corporation Isolated polynucleotides encoding PKA-binding proteins and methods of producing the proteins recombinantly
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide

Also Published As

Publication number Publication date
CA2288215C (en) 2009-08-18
US20050250727A1 (en) 2005-11-10
JP2002501499A (ja) 2002-01-15
DE69804125D1 (de) 2002-04-11
DE69804125T2 (de) 2002-10-31
JP2010111688A (ja) 2010-05-20
CA2288215A1 (en) 1998-11-05
NO971997D0 (no) 1997-04-29
PT1024809E (pt) 2002-07-31
WO1998048809A1 (en) 1998-11-05
EP1024809A1 (de) 2000-08-09
NZ501181A (en) 2002-03-01
EP1024809B1 (de) 2002-03-06
DK1024809T3 (da) 2002-06-24
AU738674B2 (en) 2001-09-20
AU7086598A (en) 1998-11-24
ES2171018T3 (es) 2002-08-16

Similar Documents

Publication Publication Date Title
DE69804125D1 (de) Verwendung von immunomodulatoren
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
HUP0103617A2 (hu) Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
EA199900373A2 (ru) Фармацевтические композиции
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
AP9901478A0 (en) Compounds for the treatment of ischemia.
BR9810829B1 (pt) composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica.
ATE231148T1 (de) Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
ID27124A (id) Penghambat kinase bisiklik
AU2464601A (en) Tricyclic protein kinase inhibitors
AU7931301A (en) Method of using diketopiperazines and composition containing them
DE122012000017I1 (de) Neuartige form von s-omeprazol.
HN2000000109A (es) Trifluorbutenos nematicidas
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
ATE170868T1 (de) Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
DE69804659D1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
MY118828A (en) Substituted amino compounds and their use as substances having an analgesic effect
ATE387448T1 (de) 4,5-pyrazinoxindole als proteinkinasehemmer
ZA941021B (en) Condensed 5-membered heterocyclic compounds, processes for preparing them and pharmaceutical compositions containing these compounds.
DE68917556D1 (de) Quinolyloxazol-2-one, nützlich als Proteinkinase-C-Inhibitoren.
DE69600601D1 (de) Heterocyclische, aromatische Verbindungen, pharmazeutische und kosmetische Zusammensetzungen,die sie enthalten, und Verwendungen.
NO921382D0 (no) Amidinofenylalaninderivater, samt fremstilling, anvendelse og preparater inneholdende forbindelsene
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee